enGene (NASDAQ:ENGN) Stock Rating Lowered by Wall Street Zen

enGene (NASDAQ:ENGN) was downgraded by Wall Street Zen from a “sell” rating to a “strong sell” rating in a research report issued on Saturday.

Several other equities research analysts have also recently issued reports on ENGN. HC Wainwright cut their price target on enGene from $6.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, June 16th. Citizens Jmp downgraded enGene from an “outperform” rating to a “market perform” rating in a research report on Friday, May 8th. Citigroup lowered enGene from a “market outperform” rating to a “market perform” rating in a report on Friday, May 8th. UBS Group decreased their price target on enGene from $9.00 to $2.00 and set a “neutral” rating on the stock in a research report on Thursday, May 14th. Finally, Piper Sandler downgraded enGene from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $7.00 to $4.00 in a research note on Friday, May 8th. Four research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, enGene presently has an average rating of “Hold” and a consensus price target of $11.05.

enGene Price Performance

NASDAQ:ENGN opened at $1.82 on Friday. enGene has a 52 week low of $1.40 and a 52 week high of $12.25. The company has a debt-to-equity ratio of 0.10, a quick ratio of 12.57 and a current ratio of 12.57. The firm’s 50-day simple moving average is $1.76 and its 200 day simple moving average is $5.82. The firm has a market cap of $121.92 million, a price-to-earnings ratio of -0.84 and a beta of -0.28.

enGene (NASDAQ:ENGN) last posted its quarterly earnings data on Monday, June 15th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.05. During the same quarter in the prior year, the company posted $0.51 earnings per share. As a group, sell-side analysts predict that enGene will post -1.84 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Cresset Asset Management LLC acquired a new stake in shares of enGene in the 2nd quarter valued at $36,000. Paloma Partners Management Co bought a new position in shares of enGene in the 2nd quarter valued at $38,000. Raymond James Financial Inc. raised its holdings in shares of enGene by 383.6% during the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after buying an additional 7,932 shares in the last quarter. Citadel Advisors LLC raised its holdings in shares of enGene by 153.3% during the 3rd quarter. Citadel Advisors LLC now owns 58,370 shares of the company’s stock worth $399,000 after buying an additional 35,327 shares in the last quarter. Finally, Millennium Management LLC lifted its position in shares of enGene by 57.3% during the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock worth $140,000 after buying an additional 7,472 shares during the last quarter. 64.16% of the stock is currently owned by institutional investors and hedge funds.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.